Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Trading 05-19 13:48:35 EDT

24.53

+0.03

+0.10%

High25.00	Low23.76	Vol267.61K
Open24.27	D1 Closing24.50	Amplitude5.07%
Mkt Cap1.35B	Tradable Cap815.18M	Total Shares55.25M
T/O6.56M	T/O Rate0.81%	Tradable Shares33.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":24.525,"timestamp":1779212915323,"preClose":24.5,"halted":0,"volume":267614,"delay":0,"changeRate":0.001020408163265248,"floatShares":33238600,"shares":55248700,"eps":-2.48598,"marketStatus":"Trading","change":0.025,"latestTime":"05-19 13:48:35 EDT","open":24.27,"high":25,"low":23.7583,"amount":6562933.087092,"amplitude":0.050682,"askPrice":24.56,"askSize":200,"bidPrice":24.46,"bidSize":107,"shortable":3,"etf":0,"ttmEps":-2.48598,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779220800000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":24.5,"preHourTrading":{"tag":"盘前","latestPrice":24.58,"preClose":24.5,"latestTime":"09:25 EDT","volume":62,"amount":1510.539976,"timestamp":1779197100073,"change":0.08,"changeRate":0.003265,"amplitude":0.00898},"postHourTrading":{"tag":"盘后","latestPrice":24.5,"preClose":24.5,"latestTime":"16:40 EDT","volume":5660,"amount":138670,"timestamp":1779136858270,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.788618,"impliedVol":0.3739,"impliedVolPercentile":0.1006},"requestUrl":"/m/hq/s/MAZE/tweets","defaultTab":"tweets","newsList":[{"id":"2636001678","title":"Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001678","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001678?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:08","pubTimestamp":1779138488,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sold 1,938 shares of common stock on May 15 at USD 26 per share.The sales were reported as indirect holdings through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.Indirect holdings following the transactions were 381,073 shares in the family trust, 31,001 shares in the irrevocable trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLb2zWdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636001682","title":"Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001682","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001682?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:04","pubTimestamp":1779138261,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein exercised stock options for 15,000 shares at USD 10.42 on May 14.Bernstein sold 15,000 shares the same day at a weighted average price of USD 26.22, leaving him with no directly held common stock.He reported beneficial ownership of 222,407 stock options following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL3XFz4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635578066","title":"LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635578066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635578066?lang=en_us&edition=fundamental","pubTime":"2026-05-16 22:35","pubTimestamp":1778942155,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $57.00. Katkhuda covers th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635177127","title":"Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635177127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635177127?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Shoulder Innovations, Inc. (SI), Maze Therapeutics, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shoulder-innovations-inc-si-maze-therapeutics-inc-maze-and-pacs-group-inc-pacs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shoulder-innovations-inc-si-maze-therapeutics-inc-maze-and-pacs-group-inc-pacs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4581","XBI","BK4185","BK4137","HCSG","BK4082","MAZE","BK4211","LU0029874061.USD","LU0128526141.USD","SI","BK4007","PACS","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635693437","title":"Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2635693437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635693437?lang=en_us&edition=fundamental","pubTime":"2026-05-14 10:27","pubTimestamp":1778725658,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) opened Q1 2026 with revenue of US$20 million and a basic EPS loss of US$0.45, alongside a net income loss of US$24.21 million, setting an earnings-season tone that is still firmly focused on managing losses. Over the past few quarters the company has gone from zero reported revenue in each quarter of 2025 to US$20 million in Q1 2026. Quarterly basic EPS has ranged from a loss of US$1.15 in Q1 2025 to a loss of US$0.45 in the latest period, putting the spotlight on how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-q1-loss-of-us242-million-reinforces-b","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-q1-loss-of-us242-million-reinforces-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782241","title":"Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782241?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:36","pubTimestamp":1778675801,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $48.00. Chico cover...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635784009","title":"Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635784009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635784009?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:15","pubTimestamp":1778674532,"startTime":"0","endTime":"0","summary":"Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Maze Therapeutics, Inc., retaining the price target of $57.00. Rami Katkhuda ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reiterated-57-price-target-maintained-on-strong-balance-sheet-and-advancing-kidney-disease-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-reiterated-57-price-target-maintained-on-strong-balance-sheet-and-advancing-kidney-disease-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789606","title":"J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789606?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:20","pubTimestamp":1778671220,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Anupam Rama reiterated a Buy rating on Maze Therapeutics, Inc. yesterday and set a price target of $58.00. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0795875169.SGD","LU1791710582.SGD","LU0971096721.USD","BK4127","BK4581","IE00BZ1G4Q59.USD","LU1244550221.USD","LU0795875086.SGD","LU0106831901.USD","LU2028103732.USD","LU1732800096.USD","LU2357305700.SGD","LU2271345857.HKD","LU0390134368.USD","LU1244550577.SGD","LU1720051017.SGD","LU2133065610.SGD","MAZE","LU2089284900.SGD","LU1791710400.SGD","LU2264538146.SGD","LU2023251221.USD","LU1162221912.USD","LU0006306889.USD","LU1244550494.USD","LU0882574139.USD","BK4516","BK4588","LU1989772840.SGD","BK4534","LU0158827781.USD","LU0528227936.USD","LU0234570918.USD","LU0225283273.USD","LU0098860793.USD","LU2089283258.USD","LU1732799900.SGD","LU1668664300.SGD","BK4007","BK4585","LU0106261372.USD","LU0158827948.USD","BK4504","LU0912757837.SGD","LU1363072403.SGD","LU1064131342.USD","LU0314104364.USD","LU1989772923.USD","LU2111349929.HKD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635322481","title":"Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635322481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635322481?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:20","pubTimestamp":1778631605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA) and Maze Therapeutics, Inc. (MA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kura-oncology-kura-and-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kura-oncology-kura-and-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4566","LU0353189763.USD","LU2462157665.USD","LU1989764664.SGD","LU2462591350.SGD","LABU","LU0061474705.USD","LU0943347566.SGD","LU0985320562.USD","LU1145028129.USD","IE00BFXG0V08.USD","BK4137","LU0823434583.USD","IE00BYQQ9H92.USD","HCSG","MAZE","LU2552382058.USD","LU0390134368.USD","LU1551013342.USD","LU1868836591.USD","LU0640476718.USD","MA","XLV","LU1623119135.USD","IE000WAW04H5.SGD","LU0128526141.USD","LU1119994496.HKD","IE000SO60NU8.SGD","LU0056508442.USD","IE0004091025.USD","LU0820561818.USD","IE0004086264.USD","LU0345769631.USD","LU0029874061.USD","LU2092627202.USD","LU2023250330.USD","LU1852331112.SGD","XBI","LU0708995401.HKD","LU2756315664.SGD","LU1261432733.SGD","LU2168563687.JPY","LU2764263039.SGD","LU1814569148.SGD","KURA","SG9999001424.SGD","LU0320765059.SGD","LU0210533765.USD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635255142","title":"Maze Therapeutics reports Q1 EPS (45c), consensus (63c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635255142","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635255142?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:36","pubTimestamp":1778621799,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q1-eps-45c-consensus-63c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q1-eps-45c-consensus-63c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635865228","title":"Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635865228","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635865228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:34","pubTimestamp":1778618090,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.56) by 19.64 percent. This is a 60.87 percent increase over losses of $(1.15) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52507770/maze-therapeutics-q1-eps-0-45-beats-0-56-estimate-sales-20-000m-beat-9-286m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240829","title":"Maze Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240829","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240829?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:17","pubTimestamp":1778617049,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMaze Therapeutics Inc MAZE.OQ reported a quarterly adjusted loss of 45 cents per share for the quarter ended Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P31Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247154","title":"Maze Therapeutics posts smaller than expected Q1 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247154?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:09","pubTimestamp":1778616552,"startTime":"0","endTime":"0","summary":"Maze Therapeutics posts smaller than expected Q1 lossOverviewUS biopharmaceutical firm reported a Q1 net loss smaller than analyst expectationsLoss from operations was narrower than expectedCompany re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635045242","title":"Maze net loss narrows to $24.2 million in Q1 FY26; revenue swings to $20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635045242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635045242?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616126,"startTime":"0","endTime":"0","summary":"Maze Therapeutics posted a narrower net loss of USD 24.2 million, or USD 0.45 per share, for quarter ended March 31, 2026.Revenue swung to USD 20 million from no revenue a year earlier, tied to a Shionogi milestone under the MZE001 license.R&D expense climbed to USD 34.1 million, while G&A expense rose to USD 12.4 million.Cash, cash equivalents, marketable securities totaled USD 362.9 million at March 31, 2026; cash runway expected to extend into 2029 including April 2026 net proceeds from a USD 150 million registered offering and a USD 20 million milestone payment.Reported positive Phase 2 HORIZON topline data for MZE829 in broad AMKD, showing a 35.6% mean uACR reduction at week 12; plans pivotal trial initiation in first half of 2027, subject to regulatory feedback.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1XqS37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4112","BK4585","SG9999014013.SGD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4007","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242733","title":"Press Release: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242733?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:01","pubTimestamp":1778616060,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027. Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026. Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029. 30% reduction in uACR. In patients with severe focal segmental","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4604","BK4585","BK4099","MAZE","TM","03160","FSGS","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632506647","title":"Maze Therapeutics CSBO Atul Dandekar disposes 7,500 shares for $190,299","url":"https://stock-news.laohu8.com/highlight/detail?id=2632506647","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632506647?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:19","pubTimestamp":1777666755,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 common shares at USD 10.42 on April 29, 2026.Directly held common shares totaled 10,503 following transactions.Stock options beneficially owned totaled 44,143 following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL2Nr98G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar disposes 7,500 shares for $190,299","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631395235","title":"Maze Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631395235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631395235?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:52","pubTimestamp":1777409555,"startTime":"0","endTime":"0","summary":"Maze Therapeutics scheduled 2026 annual stockholder meeting for June 8, 2026 via virtual meeting.Vote planned on election of two Class I directors: Jason Coloma, Neil Kumar.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL8hBx3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629786832","title":"Wedbush Cuts Price Target on Maze Therapeutics to $48 From $58, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629786832","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629786832?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:12","pubTimestamp":1776949953,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $63.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076510","title":"Maze Therapeutics prices $150 million equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076510","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629076510?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:44","pubTimestamp":1776894249,"startTime":"0","endTime":"0","summary":"The latest update is out from Maze Therapeutics, Inc. ( ($MAZE) ). On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered off...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-prices-150-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-prices-150-million-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629211910","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway","url":"https://stock-news.laohu8.com/highlight/detail?id=2629211910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629211910?lang=en_us&edition=fundamental","pubTime":"2026-04-23 02:01","pubTimestamp":1776880908,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, YeswayWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL6N4150PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STX","YSWY","ADBE","OTIS","KYTX","BOEG","HLTC","HLXX","BOED","INBX","MSTP","3LMI.UK","TH","NWMX","TEL","NVR","ISRG","COIN","DHR","GEV","MAS","TSLY","NEM","TSLA","07766","MSTR","CDE","TSLS","07799","IMST","BSX","HL","CALX","MSTK","DGX","BBY","SPWR","WAB","BA","DJT","RIOT","TFX","HOOD","T","TWLO","PM","NKTR","MAZE","CERT","AMRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":-0.1278},{"period":"3month","weight":-0.4784},{"period":"6month","weight":-0.3106},{"period":"1year","weight":1.6486},{"period":"ytd","weight":-0.4086}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction